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Background: Biliary cancers are highly aggressive tumors that are often diagnosed an advanced disease stage and
have a poor outcome with systemic therapy. Recent efforts towards molecular characterization have identified a
subset of biliary patients that have HER2/neu amplification or mutation. HER2/neu amplification is associated with
response to HER2/neu-directed therapy in breast and gastric cancers. However, the efficacy of HER2/neu-targeted
therapy in biliary cancers is unknown.
Patients and methods: We retrospectively reviewed cases of advanced gallbladder cancer and cholangiocarcinoma
with HER2/neu genetic aberrations or protein overexpression who received HER2/neu-directed therapy between
2007 and 2014. Clinical data were retrieved from medical records, and imaging studies were independently reviewed.
Results: Nine patients with gallbladder cancer and five patients with cholangiocarcinoma had received HER2/neu-
directed therapy (trastuzumab, lapatinib, or pertuzumab) during the study period. In the gallbladder cancer group,
HER2/neu gene amplification or overexpression was detected in eight cases. These patients experienced disease
stability (n = 3), partial response (n = 4), or complete response (n = 1) with HER2/neu-directed therapy. One patient
had HER2/neu mutation and experienced a mixed response after lapatinib therapy. The duration of response varied
from 8+ to 168 weeks (median 40 weeks), and three patients are still on therapy. One patient developed HER2/neu
amplification as a secondary event after FGFR-directed therapy for FGF3-TACC3 gene fusion. The cholangiocarcinoma
cases treated in this series had a higher proportion of HER2/neu mutations, and no radiological responses were seen
in these patients despite HER2/neu-directed therapy.
Conclusions: HER2/neu blockade is a promising treatment strategy for gallbladder cancer patients with gene
amplification and deserves further exploration in a multi-center study.
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Gallbladder cancer is one of the most aggressive solid
tumors and represents an important cause of cancer-
related mortality in South America and South Asia, while
occurring less frequently in the United States and West-
ern Europe. Late stage at presentation, early occurrence
of liver and peritoneal metastases, and poor outcome
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creativecommons.org/publicdomain/zero/1.0/prognosis of gallbladder cancer. Understanding the mo-
lecular characterization of this disease may help alter the
dismal outcome with targeted therapeutics [1, 2]. An esti-
mated 12–15 % of gallbladder cancers have HER2/neu
amplification or protein overexpression using commonly
accepted criteria for positivity [2–4]. Cholangiocarci-
noma is increasing in incidence in the Western world.
Recent efforts at molecular characterization have identi-
fied distinct subsets with prognostic and therapeutic
implications [5]. HER2/neu mutation or amplification
has also been reported in cholangiocarcinoma [6–8].
These patients may be candidates for HER2/neu-directed
therapy.
The HER2/neu gene is located on the 17q12-q21
chromosomal region and acts as an oncogene in severalcle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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either as the product of gene amplification or transcrip-
tional deregulation, is observed in approximately 20 % of
breast and ovarian cancers and 12 % of gastric cancers
[10]. The overexpression and amplification of HER2/neu
has also been demonstrated in gastricesophageal and
endometrial cancer, and in these tumors, it is also usually
associated with a worse prognosis [11–14]. The HER2/
neu receptors after dimerization can transactivate a num-
ber of downstream pathways like RAS-RAF-MEK-ERK1/
2 or PI3k-AKT-mTOR resulting in cancer cell prolifera-
tion and cell survival [15, 16].
Several therapeutic agents have been developed for
HER2/neu positive breast cancer: these include monoclo-
nal antibodies such as trastuzumab and pertuzumab, small
molecule tyrosine kinase inhibitors like lapatinib, and
chemo-immunotherapy conjugates like ado-trastuzumab
emtansine (T-DM1). These have substantially changed
the management of breast and gastric cancers and have
already been incorporated into standardized treatment
algorithms [11, 17, 18]. However, data in regards to the




All patients selected had pathologically confirmed gall-
bladder or biliary adenocarcinoma, had received HER2/
neu-directed therapy, and had a minimum of 3 months
of follow-up. Clinical, pharmacy, and pathology records
were reviewed to identify cases that were HER2/neu posi-
tive and had received HER2-directed therapy. The study
was approved by the Institutional Review Board of MD
Anderson Cancer Center. Patient demographics, clinical
data, survival data, and treatment history were retrieved
from medical records.
Tumor samples
Paraffin embedded blocks were sectioned, and hema-
toxylin and eosin (H&E) stained slides were reviewed by
surgical pathology to confirm the tumor content in each
section. Ten serial sections (4 μm) were cut from
selected tissue blocks and areas with tumor tissue were
macrodissected from those slides using the H&E slides
as templates.DNA extraction
The pathologic diagnosis of each case was confirmed
on routine H&E slides. All samples sent for DNA extrac-
tion contained a minimum of 20 % DNA derived from
tumor cells. DNA was extracted from 40 mm of fresh
frozen, paraffin-embedded (FFPE) tissue using the Max-
well 16 FFPE Plus LEV DNA Purification kit (PromegaCorporation, Madison, WI, USA) and quantified using a
standardized PicoGreen fluorescence assay (Invitrogen,
Carlsbad, CA, USA).Next-generation sequencing (NGS)
For subjects with adequate biopsy tissue, an amplicon
library was generated from 10 ng of DNA from each
sample using the Ion Ampliseq Cancer Panel (Life Tech-
nologies, Carlsbad, CA, USA). FFPE cell pellets of the
H2122 cell line diluted in the HL60 cell line were used
as control. The 46 genes in the panel for detection of
targetable mutations included the following: AKT1, BRAF,
FGFR1, GNAS, IDH1, FGFR2, KRAS, NRAS, PIK3CA,
MET, RET, EGFR, JAK2, MPL, PDGFRA, PTEN, TP53,
FGFR3, FLT3, KIT, ERBB2, ABL1, HNF1A, HRAS, ATM,
RB1, CDH1, SMAD4, STK11, ALK, SRC, SMARCB1,
VHL, MLH1, CTNNB1, KDR, FBXW7, APC, CSF1R,
NPM1, SMO, ERBB4, CDKN2A, NOTCH1, JAK3, and
PTPN11. Primers for PCR amplification included the
190-primer pair pool provided by the vendor with an add-
itional primer pair that was custom added to cover the
“hotspot” location on codon 17 of AKT1. Following PCR
amplification of target sequences, barcodes were ligated
to the amplicons using the Ion Xpress Barcode Adaptors
Kit (Life Technologies, Carlsbad, CA, USA). Library quan-
tification was then performed using the Bioanalyzer High
Sensitivity DNA Chip (Agilent Technologies, Santa Clara,
CA, USA). The library was diluted in nuclease-free water
to obtain a final concentration of 16 pM. Emulsion PCR
was performed manually using the Ion Xpress Template
Kit (Life Technologies, Carlsbad, CA, USA) followed by
manual breaking of the emulsion to isolate the ion spheres
(ISPs). The quality of the DNA following PCR was mea-
sured using the Qubit IonSphere Quality control kit (Life
Technologies, Carlsbad, CA, USA).
Selective ISPs with DNA were isolated and sequenced
on an Ion 316 Chip (four samples/chip) or a Ion 318
Chip (eight samples/chip) using the vendor-provided
sequencing kit (Life Technologies, Carlsbad, CA, USA).
Successful sequencing of a sample required at least
300,000 reads with a quality score of AQ20 (1 misa-
ligned base per 100 bases). For a wild-type call, a mini-
mum coverage of 250× was required. As tumor specimens
were admixed with normal tissue, a minimum coverage of
500× with at least 10 % frequency was used as cutoff for a
variant to be considered true. All variants detected by Ion
PGM with at least 10 % frequency were selected for con-
firmation by alternate platforms. Further details regarding
the methodology and analysis have been described previ-
ously [19]. For four samples, NGS was performed by
Foundation Medicine using the Illumina Hiseq 2000 Plat-
form (Illumina, San Diego, CA, USA) for 236 targetable
GAs; the methods have been described previously [20, 21].
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Tissues were fixed in formalin and embedded in paraffin
using standard techniques. The 4-μm-thick histologic
sections obtained from the TMAs were deparaffinized
and hydrated in decreasing alcohol concentrations. Anti-
gens were recovered by exposure to microwaves in
citrate buffer (pH 6.0) and washed in PBS (pH 7.4). The
monoclonal antibody anti-ErbB2 (NCL-CB11; Novocas-
tra, Leica Biosystems, Wetzlar, Germany) was used at a
dilution of 1:40. The primary antibody was incubated at
room temperature for 60 min and then incubated with
the complex Super Picture Polymer Detection Kit (Zymed
Laboratories Inc., San Francisco, CA, USA) in a Dako
autostainer (Dako, Glostrup, Denmark). Standard criteria
for HER2/Neu scoring were used [3]. Fluorescent in situ
hybridization (FISH) was performed using methods. Scor-
ing was conducted according to the College of American
Pathologists/American Society of Clinical Oncology (CAP/
ASCO) criteria for breast cancer [22].
Results
In the gallbladder cancer group, there were seven females
and two males, with a median age of 63 years. One
patient was Asian while others were Caucasian (Table 1).
All had metastatic disease; seven received trastuzumab
either alone (n = 2) or in combination with chemother-
apy (n = 5). Other HER2-directed therapies were lapati-
nib and pertuzumab. One patient who received lapatinib
had a mixed response; this patient had a HER2/neu
mutation V777L. All other cases had HER2/neu amplifi-
cation or overexpression. In all these cases, trastuzumab
was associated with partial response (n = 4), stable
disease (n = 3), or complete response (n = 1). (Figures 1,
2, 3, and 4 illustrate the responses seen in this group).
The duration of response varied from 8+ to 168 weeksTable 1 Patient characteristics













Moderate 8 4(median 40 weeks), and three patients are still on therapy.
In two cases, therapy was administered neoadjuvantly for
T4 disease and was followed by surgical resection. In one
case, disease recurrence occurred 14 months after surgi-
cal resection, which was again successfully salvaged with
trastuzumab (Fig. 1). Details regarding prior therapy
administered, concurrent chemotherapy, and duration of
treatment are described in Table 2.
One patient had FGF3-TACC3 fusion gene and had
received prior therapy with the FGFR-directed agents
pazopanib and dovitinib. Repeat biopsy after these ther-
apies indicated that the tumor had developed HER2/neu
amplification as a secondary event, while this was absent
at initial diagnosis. This finding was confirmed by FISH
analysis of the tumor biopsy before and after the FGFR-
directed therapy. In this case, disease stability or re-
sponse was noted after FGFR-directed therapy as well as
from trastuzumab. This was also accompanied by a
CA19-9 response (Fig. 5a–c).
In the cholangiocarcinoma group, the median age was
59 years; all patients were Caucasian with stage IV dis-
ease. Two patients had HER2/neu mutations (V777L
and S310F) while the others had amplification using
FISH or NGS (Table 3). Associated mutations noted on
NGS along with response data are depicted in Table 4.
All but one had received prior therapy, and two patients
received no concurrent chemotherapy. In case of cholan-
giocarcinoma, no responses occurred from trastuzumab
therapy, unlike the case with gallbladder cancer. In all
cases, HER2/neu-directed therapies were well-tolerated
without any notable cardiac events despite the length of
therapy.
Discussion
HER2/neu gene is a key driver of tumorigenesis and
its overexpression as a result of gene amplification is a
critical target for therapy in breast cancer. Other solid
tumors with reported overexpression of this gene include
gastric adenocarcinoma (11 %), pulmonary adenocarcin-
oma (28 %), colorectal adenocarcinomas (17 %), pulmon-
ary squamous (11 %), and pancreatic adenocarcinoma
(7 %). There are several existing reports of HER2/neu
overexpression in gallbladder cancer and the incidence
has varied widely, depending upon the method used for
assessment and scoring technique. Our group recently
studied HER2/neu expression in 187 cases of gallbladder
cancer; this is the largest reported series to date using
the commonly accepted CAP/ASCO criteria. We noted
than 13 % of patients have HER2/neu overexpression
(3+ by immunohistochemistry). Yoshikawa and colleagues
reviewed 236 cases of surgically resected cholangiocarci-
noma and reported a 0.9 and 8.5 % incidence of HER2/
neu expression in intra- and extrahepatic cholangiocar-
cinoma, respectively. In their series, early stage disease
Fig. 1 A 61-year-old female with gallbladder carcinoma invading the liver. Axial contrast-enhanced CT images demonstrate a a 2.4 × 1.3 cm polypoid
mass (small arrowheads) in the gallbladder neck causing gallbladder obstruction. The mass directly invades the liver, with a 2.9 × 3.9 cm liver mass
(arrow). b After 3 months of trastuzumab and FOLFOX, the polypoid gallbladder mass is no longer visualized, and the liver mass decreased
to 1.2 × 1.1 cm (arrow). The patient was then treated with en bloc cholecystectomy and extended right hepatectomy, followed by capecitabine and
trastuzumab for 7 months. c After 6 months of observation (14 months after surgery), the patient had small volume recurrence to retroperitoneal
lymph nodes (large arrowheads). After treatment with FOXFOX and trastuzumab for 3 months, d a previously seen 1-cm retroperitoneal lymph node
is nearly imperceptible
Fig. 2 A 64-year-old female with recurrent gallbladder carcinoma. Axial contrast-enhanced CT images demonstrate a a 1.2-cm nodule (arrowhead)
in the gallbladder fossa adjacent to the hepatic flexure and b a 1.7-cm nodule (arrow) in the portocaval region. Both nodules were new from the
postoperative scan (following resection of recurrent tumor in the gallbladder fossa), in keeping with recurrence. c, d Thirteen months later, both
nodules are stable after treatment with trastuzumab
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Fig. 3 A 62-year-old female with recurrent metastatic gallbladder carcinoma with carcinomatosis. Axial contrast-enhanced CT images demonstrate
a enhancing perihepatic nodules (arrowheads), b a 4.8-cm metastasis destroying the sternum (arrow), and c a 1.8-cm lung metastasis (circle). After
3 months of trastuzumab, d the perihepatic nodules are no longer visualized. e The sternum has become sclerotic with decreased size of the
metastasis (arrow), and f the lung metastasis has undergone cavitation (circle).
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of HER2/neu positivity. Data with regard to the prog-
nostic value of HER2/neu overexpression in biliary cancers
is mixed, with some studies suggesting a worse prognosis
[23, 24], while others suggest the contrary [25, 26].
NGS for HER2/neu gene amplification may be re-
garded as the gold standard. However, this technology is
dependent upon the quality of the pathological sample
and DNA degradation may result from formalin fixation.
In our retrospective series, the criteria for HER2/neu
positivity were stringent and included 3+ protein expres-
sion on immunohistochemistry, FISH ratio higher than
2.2 or HER2/neu genetic aberration in a Clinical Labora-
tory Improvement Amendment (CLIA) compliant labora-
tory. Slamon and others have described the remarkable
success of HER2/neu-targeted therapy for breast cancer[27–29]. In gastric cancer, the trastuzumab for gastric
adenocarcinoma (ToGA) trial established the benefit of
trastuzumab in combination with a fluoropyrimidine plus
cisplatin in a randomized phase 3 trial of gastric cancer
patients with overexpression or gene amplification of
HER2/neu [30]. It is logical therefore to investigate HER2/
neu targeting in other cancers that have gene amplifica-
tion or overexpression.
Although the number of cases in this retrospective
review is limited, to our knowledge, this is the largest
reported case series of gallbladder cancer with HER2/
neu amplification or overexpression treated with tar-
geted therapy. Our experience demonstrates that HER2/
neu-directed therapy appears to be beneficial for gall-
bladder cancer cases with HER2/neu amplification. Only
one case in our series failed to respond, this tumor had
Fig. 4 A 45-year-old female with metastatic gallbladder carcinoma. Axial contrast-enhanced CT images demonstrate a a 1.5-cm liver metastasis
(arrowheads) and b prominent soft tissue (arrows) in the cholecystectomy bed abutting the liver. After 2 months of treatment with trastuzumab,
c the liver metastasis is barely visible at 4 mm, and d the soft tissue mass in the resection bed, representing recurrent tumor, is decreased. She
was stable for an additional 5 months, then had recurrence in the resection bed
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prior case reports have described responses with trastu-
zumab in subjects with gallbladder cancer. In the first, a
45-year-old woman received paclitaxel and trastuzu-
mab and a dramatic regression of her lung metastasesTable 2 Gallbladder cancer: prior therapy , concurrent chemotherap













































9 Lungs, brain Gemcitabine + cisplatin
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IHC 3+ Tra
HER2-positive tumors IHC 3+, FISH HER2/centromere 17 ratio ≥2.0 or both
SD stable disease, MR mixed response, PR partial responseoccurred [31]. In the second, a 61-year-old woman
also with gallbladder cancer had a remarkable response
to weekly paclitaxel and trastuzumab, which persisted
when trastuzumab was continued as a single agent [32].
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Fig. 5 A 73-year-old female with metastatic retroperitoneal lymphadenopathy from gallbladder carcinoma. Axial contrast-enhanced CT images
demonstrate a a 1.9-cm lymph node (arrowheads) posterior to the left renal vein. After 2 months of trastuzumab and pertuzumab, b the lymph
node decreased to 1.2 cm. c Her CA 19-9 response to HER2/neu inhibition after prior FGFR inhibitor therapy
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geted therapy for those with HER2/neu amplification
would be substantial.
In this review, we also report a patient with gallblad-
der cancer with FGF3-TACC3 fusion gene with nega-
tive HER2/neu gene amplification on NGS (confirmed
by IHC and FISH, both being negative) who was treated
with targeted FGFR inhibitors (dovitinib followed by pazo-
panib) resulting in initial response. She underwent repeatTable 3 Cholangiocarcinoma: prior therapy , concurrent chemother
Pt # Sites of disease Prior therapy HER2/neu test
1 Liver, mediastinum,
Lung
Gemcitabine folfirinox Mutation (NGS)
V777L
2 Liver, peritoneum, lung Gemcitabine + cisplatin ERBB2 amp NGS
3 Mediastinum Gemcitabine + cisplatin,
FOLFIRI, GTX
ERBB2 NGS S310F
4 Liver, lung Nil AMPLIFIED (FISH)
5 Lung, liver, bones Gemcitabine + cisplatin AMPLIFIED (FISH)
HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥2.0 or both
SD stable disease, PD progressive disease, CR complete response, PR partial responstumor biopsy on disease progression that then showed
HER2/neu amplification on NGS (confirmed by IHC and
FISH). In this case, we hypothesize that the HER2/neu
amplification was a secondary event leading to resistance
to FGFR inhibitors. Interestingly, FGFR2 addiction has
been reported to be a mechanism leading to lapatinib re-
sistance in breast cancer [33]. However, to our knowledge
this is the first report of HER2/neu amplification as a









Trastuzumab Gemcitabine, docetaxel 19 29 PD
Trastuzumab FOLFOX 14 25 PD
Trastuzumab FOLFOX 7 7 PD
Trastuzumab 6 8 PD
Trastuzumab 10 12 PD
e
Table 4 Associated mutations noted on NGS along with response data






Cholangioca Mutation (V777L) FGFR3, TP53 SD Trastuzumab 19 29
Cholangioca Amplification BAP1, CDKN2A, KDM6A, PBRM1, SETD2 PD Trastuzumab 14 25
Cholangioca Mutation (S310F) KRAS, MYC, TP53, EZH2, MSH6 PD Trastuzumab 7 7
Cholangioca Amplification PD Trastuzumab 6 8
Cholangioca Amplification PD Trastuzumab 10 12
Gallbladder cancer Amplification PIK3CA, CDKN2A/B, TP53, ZNF703 MR Lapatinib 15 19
Gallbladder cancer Amplification TP53 PR Trastuzumab >92 >92
Gallbladder cancer Amplification NRAS, PIK3CA, RB1,PTEN, TP53 PR Trastuzumab >40 >62
Gallbladder cancer Amplification PR Trastuzumab 168 178
Gallbladder cancer Amplification PR Trastuzumab 38 113
Gallbladder cancer Amplification FGFR3-TACC3 fusion, TP53, CCNE1, MCL1, MYC SD Trastuzumab + pertuzumab +8 +8
SD stable disease, PD progressive disease, MR mixed response, PR partial response
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disease progression for re-assessment of HER2/neu status
in select cases.
In contrast, trastuzumab was less effective in the case
of cholangiocarcinoma and there were no responses
noted in our series. Two of these cases with cholangio-
carcinoma had HER2/neu mutations, which are not
known to be responsive to trastuzumab, but may poten-
tially respond to tyrosine kinase inhibitors like lapatinib,
neratinib, and canertinib [34]. HER2/neu-targeted ther-
apy has also not proven to be effective despite the pres-
ence of gene amplification in diseases like colon and
pancreas cancers. The reason for this lack of efficacy is
not known. Junttila et al. demonstrated that trastuzumab
disrupts ligand-independent ErbB2/ErbB3/PI3K com-
plexes blocking AKT signaling; when PI3K is mutated or
dysfunctional, complex disruption does not inhibit AKT
[35]. Another possible explanation could involve the
higher rate of KRAS mutations seen in intrahepatic cho-
langiocarcinomas as compared with gallbladder cancers,
possibly mediating resistance to upstream HER2 block-
ade [2, 5, 36].
In summary, HER2/neu-directed therapy is a promis-
ing avenue for patients with gallbladder cancer with gene
amplification and should be further explored in an inter-
national clinical trial.Competing interests
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